Literature DB >> 2838046

The requirement of lipids for the formation of immunostimulating complexes (iscoms).

K Lövgren1, B Morein.   

Abstract

The iscom--immunostimulating complex--is a highly immunogenic formulation of microbial membrane antigens. The biochemically analyzed components of the iscom are the protein and the glycoside Quil A. Continued analysis of the iscom showed that the protein moiety--the antigen--does not contribute to the iscom as a construct. Instead, cholesterol and Quil A are the essential structural components assembled together into a typical cage-like structure. A more "fluid" lipid, such as phosphatidylcholine, is needed to facilitate the incorporation of amphipathic poly- or oligopeptides into the iscom matrix.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2838046

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN： 0885-4513            Impact factor:   2.431


  28 in total

1.  An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration.

Authors:  K Lövgren; H Kåberg; B Morein
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

2.  The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes.

Authors:  Neil C Robson; Helen Beacock-Sharp; Anne M Donachie; Allan McI Mowat
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

3.  Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51.

Authors:  M Merza; J Söber; B Sundquist; I Toots; B Morein
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

4.  Protein and modified vaccinia virus Ankara-based influenza virus nucleoprotein vaccines are differentially immunogenic in BALB/c mice.

Authors:  A F Altenburg; S E Magnusson; F Bosman; L Stertman; R D de Vries; G F Rimmelzwaan
Journal:  Clin Exp Immunol       Date:  2017-07-24       Impact factor: 4.330

5.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

6.  Immune responses and resistance to Toxoplasma gondii in mice immunized with antigens of the parasite incorporated into immunostimulating complexes.

Authors:  A Lundén; K Lövgren; A Uggla; F G Araujo
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

7.  Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.

Authors:  M T Bejarano; M G Masucci; A Morgan; B Morein; G Klein; E Klein
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

8.  Immunity against Yersinia enterocolitica by vaccination with Yersinia HSP60 immunostimulating complexes or Yersinia HSP60 plus interleukin-12.

Authors:  A Noll
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

9.  The induction of cell-associated and secreted IL-1 by iscoms, matrix or micelles in murine splenic cells.

Authors:  M Villacres-Eriksson; M Bergström-Mollaoglu; H Kåberg; K Lövgren; B Morein
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

10.  Antigen presentation by naive macrophages, dendritic cells and B cells to primed T lymphocytes and their cytokine production following exposure to immunostimulating complexes.

Authors:  M Villacres-Eriksson
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.